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Background: Cyclooxygenase (COX)-2, a key regulatory enzyme in prostanoid synthesis, plays an important role in inflammatory processes.
The 765G>C COX-2 polymorphism has been associated with lower promoter activity in vitro and reduced levels of C-reactive protein
(CRP) in atherosclerotic carriers of the C allele. However, its pathophysiological relevance in vivo has not been fully elucidated.
Methods and results: We assessed the 765G>C polymorphism and COX-2 expression in 220 asymptomatic subjects free of
cardiovascular disease, in relation to global vascular risk, carotid intima-media thickness (IMT), and inflammatory markers (fibrinogen, C-
reactive protein [CRP], von Willebrand factor [vWF] and interleukin-6 [IL-6]). Genotype frequencies were: CC (7.7%), CG (34.5%), GG
(57.7%). Among hypercholesterolemic subjects (n =140), C allele carriers had lower COX-2 expression ( p <0.05), reduced carotid IMT
( p <0.01) and diminished levels of inflammatory markers CRP, vWF and IL-6 ( p <0.05), as compared to GG homozygous subjects. The
association between carotid IMT and COX-2 polymorphism remained significant after adjusting for cardiovascular risk factors and
inflammatory markers ( p =0.008).
Conclusions: In asymptomatic hypercholesterolemic subjects the C allele of 765G>C COX-2 polymorphism was associated with lower
COX-2 expression, and reduced subclinical atherosclerosis and systemic inflammation compared with GG homozygous, thus conferring
atherosclerosis protection in this cardiovascular risk population.
D 2005 Elsevier B.V. All rights reserved.Keywords: Atherosclerosis; COX-2 polymorphism; Hypercholesterolemia; Inflammation1. Introduction
COX-1 and COX-2 catalyze the rate-limiting step in
prostanoid synthesis, converting arachidonic acid into
PGH2, the precursor of a family of bioactive prostanoids,
including thromboxane (TXA2) and prostaglandins (PGs)
[1,2]. COX-1 is a widely expressed constitutive enzyme that
participates in tissue homeostasis. By contrast, COX-2, the
inducible isoform, is expressed at low levels in most tissues0009-8981/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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E-mail address: josuneor@unav.es (J. Orbe).but can be stimulated by LPS, growth factors and cytokines,
such as TNF-a and interleukin-6 (IL-6) [3,4], being
implicated in inflammatory processes, including atheroscle-
rosis, rheumatoid diseases and carcinogenesis [5–7]. A
direct role for COX-2 in atherosclerosis can be inferred from
studies showing significant expression in human athero-
sclerotic lesions [8–10], as well as COX-2-derived PGE2
increase in subclinical atherosclerosis [11,12]. Paradoxical-
ly, recent evidence points to a protective function of this
enzyme in cardiomyocytes subjected to oxidative stress [13]
and also in late preconditioning after ischemia/reperfusion
injury [14]. Thus, it is likely that COX-2 exerts beneficial or
detrimental effects depending on the rate of induction, the
pathophysiological setting and the ability of specific cells to8 (2006) 138 – 143
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prostanoids [15].
Genetic polymorphisms in COX-2 might have an impact
on COX-2 expression and prostanoid biosynthesis. Al-
though several naturally occurring polymorphisms have
been found in the COX-2 gene, their functional relevance
and pathophysiological role remain to be elucidated [16,17].
Recently, Papafili et al. have described a common variant in
the 5V-flanking region of the COX-2 gene 765G>C that is
associated with lower promoter activity in vitro in the
presence of the C allele, and reduced levels of C-reactive
protein (CRP), a systemic marker of inflammation, in
patients with clinical and subclinical atherosclerosis. This
single nucleotide polymorphism (SNP) has also been
associated with a reduction in the risk of future clinical
cardiovascular events [17,18].
We therefore assessed COX-2 expression, subclinical
atherosclerosis and inflammatory profile, in relation to this
polymorphism, in subjects with cardiovascular risk factors
but free of clinically overt atherosclerotic disease.2. Methods
2.1. Subjects
A total of 220 apparently healthy subjects (80% males,
median age 58 years), referred to the Internal Medicine
Department of a single institution (University Clinic of
Navarra) for global vascular risk assessment, were studied.
Subjects were free from clinically apparent atherosclerotic
disease based on (1) absence of history of coronary disease,
stroke or peripheral arterial disease, and (2) normal ECG
and chest-X-ray. Baseline clinical characteristics, cardiovas-
cular risk factors and metabolic parameters in this popula-
tion are summarized in Table 1. Exclusion criteria were theTable 1
Biochemical parameters and cardiovascular risk factors in subjects
classified according to the 765G>C polymorphism in the promoter of
COX-2 gene
CC (n =17) CG (n =76) GG (n =127)
Age (years) 57.1T9.8 56.5T10.1 59.4T10.7
Sex (male, %) 76.4 80.2 75.8
Glucose (mg/dL) 105.2T42.3 106.9T35.5 103.4T29.3
Total cholesterol (mg/dL) 218.5T48.1 229.4T35.4* 214.9T42.0
LDL-cholesterol (mg/dL) 147.3T38.8 157.1T31.7** 142.3T38.5
HDL-cholesterol (mg/dL) 49.1T14.2 49.9T13.1 48.4T13.1
Triglycerides (mg/dL) 111.0T45.1 116.4T65.1 121.0T71.5
Current smokers (%) 11.8 34.3 34.4
Hypertension (%) 41.2 55.2 51.9
Dyslipidemia (%) 81.2 81.5 78.1
Obesity (%) 18.7 35.5 33.1
Diabetes mellitus (%) 17.6 9.2 11.7
COX-2 expressiona 0.12T0.05 0.13T0.1 0.14T0.1
*p <0.05, ** p <0.01 vs. GG.
a Normalized mRNA=target gene mRNA copies/h-actin mRNA copies.presence of severely impaired renal function, arteritis,
connective tissue diseases, alcohol abuse or use of
nonsteroidal anti-inflammatory drugs in the 2 weeks before
entering the study. Other conventional atherosclerotic risk
factors recorded were: hypertension (systolic/diastolic blood
pressure >139/89 mm Hg and/or use of antihypertensive
drugs), obesity (body mass index 30 kg/m2), smoking
(1 cigarette a day), diabetes (fasting glucose 126 mg/
dL and/or use of pharmacologic treatment), and family
history of premature CHD (acute myocardial infarction
before 60 years in a first degree relative). A subset of 140
hypercholesterolemic subjects was selected from the total
population, on the basis of the following criteria: total
cholesterol 220 mg/dL, LDL-cholesterol 130 mg/dL
and/or statin treatment. Written informed consent was
obtained before participation in the study, and the local
committee on human research approved the protocol,
which was performed in accordance with the principles
of the Helsinki Declaration.
2.2. COX-2 genotyping procedure
Peripheral blood mononuclear cells were freshly
obtained by centrifugation in a Ficoll gradient
(Lymphoprepi). Total DNA and RNAwere extracted from
these cells using Tripure Isolation Reagent (Roche). To
genotype the 765G>C variant, a fragment of 306 bp was
amplified by PCR in the presence of 60 nM of the forward
primer CF8 (5V-CCGCTTCCTTTGTCCATCAG-3V) and the
reverse primer CR7 (5V-GGCTGTATATCTGCTCTA-
TATGC-3V) as previously described [17]. Amplified product
was digested with AciI (New England Biolabs) restriction
endonuclease at 37 -C overnight and the resulting fragments
were separated by electrophoresis in a 2% agarose gel, and
visualized after ethidium bromide staining. Positive and
negative digestion controls were included in all gels.
2.3. Quantitative real-time RT-PCR for COX-2 expression in
peripheral blood mononuclear cells
Total RNA from mononuclear cells was reverse tran-
scribed, and COX-2 expression was quantified by real-time
quantitative PCR as previously described [12]. All samples
were assayed in triplicate and values normalized on the
basis of their h-actin content. Melt curve analysis was
performed to ensure that only the specific product was
amplified.
2.4. Carotid ultrasonography
All subjects underwent ultrasonography of the common
carotid arteries (CCAs). Ultrasonography was performed
with a 5–12 MHz linear-array transducer (ATL 500 HDI).
The measurement of IMT was made 1 cm proximal to the
carotid bulb of each CCA at plaque-free sites. From each
individual, the IMT was determined as the average of near-
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IMT has been shown to be reproducible [12,19].
2.5. Systemic inflammatory markers
Plasma and serum samples were obtained from venous
blood between 9 and 10 a.m. after overnight fast, and
stored at 80 -C until analysis. CRP and IL-6 concen-
trations were analyzed by a high-sensitive immunoassays
system (Immulyte hs-CRP, Diagnostic Product Corporation
and Quantikine-HS IL-6, R&D systems respectively).
Plasma fibrinogen activity was measured by a clotting
assay (Clauss). von Willebrand factor (vWF) antigen was
quantified by an enzyme-linked immunosorbent assay
(Liatest vWF, Diagnostica Stago, France). vWF values
were expressed as percentage in relation to a calibrated
standard curve.
Inter and intra-assay coefficients of variation for all these
assays were lower than 8%.
2.6. Biochemical parameters
Serum cholesterol, HDL and LDL-cholesterol, glucose
and triglycerides were determined on fasting blood samples
by standard enzymatic techniques.
2.7. Statistical analysis
MeanTSD (SE for logarithmically transformed variables)
is given for all continuous variables, and absolute numbers
and percentages for categorical variables. Differences
among genotypes were assessed by ANOVA followed by
Bonferroni post-hoc test. When no differences between CG
and CC genotypes were found, they were pooled into the
same group, and mean comparisons between genotypes
were made by the Student’s t test. Deviations of the Hardy–
Weinberg equilibrium were assessed by a v2 test. Pearson
test was performed for correlations of continuous variables.
Univariate and multivariate lineal regression analysis were
performed to assess the relationship between genotypes,
inflammatory markers and subclinical atherosclerosis after
adjustment for cardiovascular risk factors and other poten-
tial confounders. A two-tailed p <0.05 was considered
statistically significant.
The statistical analysis was performed with SPSS for
Windows software package version 11.0.3. Results
To examine the association of the 765G>C polymor-
phism with COX-2 expression, 220 asymptomatic subjects
with cardiovascular risk factors (mean age 58.1T10.3 years,
77.7% men) were genotyped for this polymorphism by PCR
analysis. Subjects carrying CC, CG and GG genotypes were
17 (7.7%), 76 (34.5%) and 127 (57.7%) respectively, andallele frequencies 0.25 and 0.75 for C and G alleles
respectively, consistent with the Hardy–Weinberg equilib-
rium. The 3 groups were comparable in relation to all
clinical and biochemical parameters analyzed (Table 1),
except for the levels of total and LDL-cholesterol, which
were significantly augmented in CG (229.4T43.1 mg/dL),
as compared to either CC (218.5T48.1 mg/dL) and GG
(214.9T42.0 mg/dL) genotypes. Since the expression of
COX-2 is regulated by LDL-cholesterol at transcriptional
level [20,21], and C allele was previously associated with
less COX-2 expression [17], a homogeneous subgroup of
subjects with similar cholesterol levels (n =140) was further
selected to assess the net effect of this SNP.
3.1. 765G>C COX-2 polymorphism in the hypercholes-
terolemic population
The clinical characteristics and cardiovascular risk
factors of the 140 asymptomatic hypercholesterolemic
subjects (mean age 59.7T9.4 years, 77.7% men) are
shown in Table 2. Mean total cholesterol levels were
232.5T38.7 mg/dL and LDL levels 158.0T35.8 mg/dL.
28% out of the total population were receiving statins and
40% of hypertensives were taking antihypertensive drugs.
The genotype distribution was as follows: CC=12
(8.6%), CG=46 (32.8%), and GG=82 (58.6%); allele
frequencies were 0.25 and 0.75 for C and G alleles
respectively, consistent with the Hardy–Weinberg equilib-
rium. Clinical and biochemical parameters analyzed in
relation to the COX-2 genotypes are also shown in Table
2. Demographic characteristics were similar in the three
groups, and there were also no significant differences
among genotypes in relation to analytical determinations
and anti-atherosclerotic therapy.
3.2. COX-2 expression in monocytes in relation to the
765G>C polymorphism
Results of COX-2 gene expression in blood peripheral
mononuclear cells in relation to 765G>C polymorphism
are shown in Table 3. The lowest baseline COX-2
expression was found in hypercholesterolemic subjects with
CC genotype (0.10 T0.04) compared with the GC
(0.13T0.02) and GG (0.14T0.01) genotypes. When assem-
bling carriers of the 765C allele, mean COX-2 expression
was significantly lower (0.11T0.06) than in GG homozy-
gous subjects ( p =0.04).
3.3. Carotid IMT in relation to the 765G>C
polymorphism
In order to investigate the association of the COX-2
polymorphism with atherosclerotic plaque development, the
carotid IMT was measured as a function of the 765GC
genotype. As shown in Fig. 1, subjects homozygous for the
C allele had significantly reduced carotid IMT (0.60T0.08
1.2
1.0
p<0.01
p<0.05
Table 2
Biochemical parameters and cardiovascular risk factors in asymptomatic hypercholesterolemic subjects classified according to the 765G>C COX-2
polymorphism
Total (n =140) CC (n =12) CG (n =46) GG (n =82)
Age (years) 59.7T9.4 60.1T8.1 58.2T9.3 60.6T9.5
Sex (male, %) 77.7 83.3 76.1 76.5
Current smokers (%) 29.7 16.7 28.3 32.5
Hypertension (%) 52.9 41.7 56.5 52.5
Obesity (%) 35.8 27.3 41.3 33.8
Diabetes mellitus (%) 11.5 8.3 8.7 13.6
SBP (mm Hg) 133.2T21.7 128.4T18.6 134.3T25.1 133.3T20.2
DBP (mm Hg) 83.4T9.6 81.8T7.4 83.7T11.0 83.5T9.1
Total cholesterol (mg/dL) 232.5T38.7 232.7T46.3 237.6T32.9 229.5T40.7
LDL-cholesterol (mg/dL) 158.0T35.8 159.2T36.2 164.3T30.5 154.3T38.4
HDL-cholesterol (mg/dL) 49.6T13.5 48.3T14.6 49.7T13.9 49.7T13.2
Triglycerides (mg/dL) 126.1T67.2 126.1T41.2 125.7T64.4 126.3T72.3
Glucose (mg/dL) 103T29.3 109.0T49.8 105.9T35.7 101.9T20.3
Statin treatment (N/Y) 101/39 10/2 33/13 58/24
Antihypertensives (N/Y) 110/30 9/3 30/16 71/11
SBP=systolic blood pressure, DBP=diastolic blood pressure.
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and GG (0.73T0.16 mm, p <0.01) genotypes.
3.4. Systemic markers of inflammation in relation to the
765G>C polymorphism
To further assess whether the 765G>C COX-2
promoter variant would influence the systemic levels of
inflammatory and endothelial activation markers, CRP, IL-
6, fibrinogen and vWF concentrations were compared in
relation to the different genotypes. As shown in Table 3,
subjects homozygous for the C allele exhibited significantly
lower concentrations of CRP (0.23 T0.03 mg/dL vs.
0.37T0.03 mg/dL, p<0.01) and vWF (79.0T23.2% vs.
108.5T45.6%, p <0.01), whereas differences in fibrinogen
levels did not reach statistical significance. Likewise,
carriers of the C allele also showed significantly lower IL-
6 levels as compared to GG homozygous (1.6T0.4 pg/mL
vs. 2.1T1.6 pg/mL, p <0.05).Table 3
COX-2 expression and inflammatory profile in relation to the COX-2
765G>C polymorphism in hypercholesterolemic subjects
CC CG GG P
(n =12) (n =46) (n =82) C allele
vs. GG
COX-2 expression
Baseline mRNAa 0.10T0.04 0.13T0.02 0.14T0.01 0.040
Inflammatory markers
CRP (mg/dL)b 0.23T0.03.. 0.29T0.02 0.37T0.03 0.022
IL-6 (pg/mL) 1.7T0.7 1.5T0.8.. 2.1T1.6 0.022
Fibrinogen (mg/dL) 291.7T85.3 299.4T63.6 304.7T87.4 ns
VWF (%) 79.0T23.2.. 118.9T42.4- 108.9T45.6 ns
-p <0.01 vs. CC.
a Normalized mRNA=target gene mRNA copies/h-actin mRNA copies.
b Logarithmically transformed (meanTSE).3.5. Multiple regression analysis
Taking into account the possible associations between
765G>C and carotid IMT with cardiovascular risk factors
and inflammatory markers, further multiple regression
analysis was performed to assess whether the reduction in
carotid IMT observed in C allele carriers was independent of
potential confounders. As shown in Table 4, the association
between both parameters remained statistically significant
after adjusting for traditional cardiovascular risk factors and
inflammatory markers ( p =0.008), with a reduction inCOX-2 genotype
CC
(n=12)
CG
(n=46)
GG
(n=82)
ca
ro
tid
 IM
T 
(m
m) 0.8
0.6
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0.2
Fig. 1. Box-plot showing the carotid IMT in relation to the 765G>C
COX-2 polymorphism. Median and percentile 75th is reported.
Table 4
Multiple linear regression analysis for the association of COX-2 765G>C polymorphism with carotid IMT in hypercholesterolemic subjects
Genotypes R (95% CI) p Ra (95% CI) pa
GG Referent – –
GC 0.18 (0.34 to 0.02) ns 0.25 (0.40 to 0.09) 0.021
CC 0.22 (0.37 to 0.06) 0.016 0.29 (0.43 to 0.13) 0.008
a Adjusted for age, gender, smoking, hypertension, obesity and diabetes, IL-6, vWF, CRP and fibrinogen.
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subjects with GG genotype.4. Discussion
In a population sample of hypercholesterolemic subjects
without clinically overt atherosclerotic disease, we show that
the common variant765G>C in the COX-2 gene promoter
can play a protective role on subclinical atherosclerosis and
systemic inflammation. Subjects carrying the C allele had
significantly lower COX-2 expression and reduced carotid
IMT, as well as diminished levels of the inflammatory
markers CRP, IL-6 and vWF, compared with GG homozy-
gous subjects. Taken together, our results indicate that the C
allele might offer some protection against clinical events
related to atherosclerosis development.
A polymorphism in the 5V-flanking region of the gene
(765G>C) has been associated with functional changes in
COX-2 promoter activity in vitro [17]. Subjects with the C
allele might be protected from systemic inflammation, since
lower levels of CRP, an established marker of inflammation
and cardiovascular risk, were observed in patients with
clinical atherosclerosis. However, there is little information
available regarding the possible influence of this polymor-
phism on COX-2 expression and atherosclerosis develop-
ment in vivo as well as its possible association with reduced
risk of cardiovascular events [17]. Recently, C allele has
been shown to be associated with reduced risk of
myocardial infarction, stroke [18] and a decreased risk of
Alzheimer’s disease [22]. Moreover, our group has shown
that COX-2-dependent PGE2 release by blood monocytes is
related to subclinical atherosclerosis in apparently healthy
subjects exposed to cardiovascular risk factors [11,12].
COX-2 expression and PGE2 synthesis have been shown to
promote the release and activation of MMPs likely involved
in plaque growth and rupture [10,23]. These data prompted
us to assess the functional relevance of that polymorphism
in relation to inflammation and subclinical atherosclerosis,
in a population of subjects free from clinically apparent
cardiovascular disease.
We found, for the first time, that in hypercholesterolemic
subjects the C allele was independently associated with
reduced carotid IMT, an established surrogate of athero-
sclerosis [24], after adjusting for traditional cardiovascular
risk factors. The model explained an 8.3% reduction in
carotid IMT in CC homozygous compared with the
remaining genotypes. These data would suggest that thispolymorphism may offer some protection against clinical
events related to atherosclerosis plaque development [25].
Since lower COX-2 expression could be demonstrated in
this subgroup, an inflammation-related effect can be
suggested on the mechanism or carotid arterial thickening
[26]. In contrast, Cipollone et al. failed to demonstrate any
effect of this SNP on lesion size in the coronary artery
assessed by angiography in a population with clinical
cardiovascular disease [18].
The fact that lower COX-2 expression was found in C
allele carriers in the present study could partially account for
a reduced COX-2-mediated inflammation-dependent plaque
growth. Supporting these observations, we also found that
the COX-2 polymorphism was associated with a reduction
in systemic inflammation, C allele carriers showing signif-
icantly lower levels of CRP, IL-6 and vWF, an effect not due
to statin treatment, since no differences in the proportion of
patients using lipid-lowering agents were found. Whereas
there are several evidences linking COX-2 expression and
inflammation, the precise mechanism remains unclear [27–
29]. An association between COX-2 and IL-6 has been
established in macrophages via PGE2 [30]; furthermore, the
magnitude of rise in CRP levels in cardiovascular patients
was also found to be strongly dependent on the 765G>C
polymorphism [17]; since IL-6 is known to regulate CRP
[31,32], it can be speculated that this polymorphism
influences CRP levels via IL-6, which is also supported
by our present findings. Subjects homozygous for the C
allele also showed lower vWF levels, suggesting reduced
endothelial damage [33] as compared with the remaining
genotypes. Whereas there are no reports of COX-2-
mediated induction of vWF, immunohistochemical studies
have shown their colocalization in endothelial cells [34].
Taken together, we found hypercholesterolemic subjects
carrying the C allele of the 765G<C COX-2 polymor-
phism exhibited a more favourable phenotypic response
consisting of reduced carotid IMT and systemic inflamma-
tion. A main difference between genetic and pharmacolog-
ical inhibition of COX-2 to protect against cardiovascular
events [28], would be in the preserved endothelial function
and reduced systemic inflammation by the SNP.
Some limitations of the present study must be recog-
nized. Our population sample was relatively small with high
male prevalence. In addition, the cross-sectional design does
not allow us to draw conclusions regarding the value of
COX-2 polymorphism in the prediction of cardiovascular
events. In the multivariate analysis we tried to adjust for
most of the possible confounders, but other genetic,
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present analysis could also influence the IMT. Finally, the
effect of this polymorphism cannot be extrapolated to other
populations at atherosclerotic risk.
In conclusion, we documented a functional effect of
765G>C polymorphism in the COX-2 promoter, causing
lower COX-2 gene expression, associated with reduced
inflammation and subclinical atherosclerosis in middle-aged
asymptomatic hypercholesterolemic subjects. Further stud-
ies in larger populations are warranted in order to validate
the clinical significance of this polymorphism for athero-
sclerotic protection in cardiovascular risk patients.
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